Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer

Ondřej Kubeček,Martínková J,Jaroslav Chládek,Milan Bláha,Jana Malakova,Miroslav Hodek,Jiří Špaček,Stanislav Filip

Plasmafiltration as an effective method in the removal of circulating pegylated liposomal doxorubicin (PLD) and the reduction of mucocutaneous toxicity during the treatment of advanced platinum-resistant ovarian cancer

2019

Ondřej Kubeček
Martínková J
Jaroslav Chládek
Milan Bláha
Jana Malakova
Miroslav Hodek
Jiří Špaček
Stanislav Filip

Purpose The present study evaluates the safety and efficacy of double-plasma filtration (PF) to remove the exceeding pegylated liposomal doxorubicin (PLD) in circulation, thus reducing mucocutaneous toxicity.

Keywords:

Mucocutaneous zone
Pegylated Liposomal Doxorubicin
cancer therapy
Toxicity
Medicine
Plasmapheresis
Pharmacology
Ovarian cancer
Doxorubicin
Adverse effect
Mucositis
Pharmacokinetics
Urology
Chemotherapy
Population

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations